Randomized, Controlled Human Challenge Study of the Safety, Immunogenicity, and Protective Efficacy of a Single Dose of Peru-15, a Live Attenuated Oral Cholera Vaccine
-
Published:2002-04
Issue:4
Volume:70
Page:1965-1970
-
ISSN:0019-9567
-
Container-title:Infection and Immunity
-
language:en
-
Short-container-title:Infect Immun
Author:
Cohen Mitchell B.1, Giannella Ralph A.2, Bean Judy3, Taylor David N.4, Parker Susan5, Hoeper Amy5, Wowk Stephen1, Hawkins Jennifer1, Kochi Sims K.6, Schiff Gilbert5, Killeen Kevin P.6
Affiliation:
1. Division of Pediatric Gastroenterology, Hepatology and Nutrition 2. Digestive Diseases, University of Cincinnati and VA Medical Center, Cincinnati, Ohio 3. Center for Epidemiology and Biostatistics 4. Walter Reed Army Institute of Research, Washington, D.C. 5. Gamble Program for Clinical Studies, Children's Hospital Medical Center 6. AVANT Immunotherapeutics, Inc., Needham, Massachusetts
Abstract
ABSTRACT
Peru-15 is a live attenuated oral vaccine derived from a
Vibrio cholerae
O1 El Tor Inaba strain by a series of deletions and modifications, including deletion of the entire CT genetic element. Peru-15 is also a stable, motility-defective strain and is unable to recombine with homologous DNA. We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. A total of 59 volunteers were randomly allocated to groups to receive either 2 × 10
8
CFU of reconstituted, lyophilized Peru-15 vaccine diluted in CeraVacx buffer or placebo (CeraVacx buffer alone). Approximately 3 months after vaccination, 36 of these volunteers were challenged with approximately 10
5
CFU of virulent
V. cholerae
O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Among vaccinees, 98% showed at least a fourfold increase in vibriocidal antibody titers. After challenge, 5 (42%) of the 12 placebo recipients and none (0%) of the 24 vaccinees had moderate or severe diarrhea (≥3,000 g of diarrheal stool) (
P
= 0.002; protective efficacy, 100%; lower one-sided 95% confidence limit, 75%). A total of 7 (58%) of the 12 placebo recipients and 1 (4%) of the 24 vaccinees had any diarrhea (
P
< 0.001; protective efficacy, 93%; lower one-sided 95% confidence limit, 62%). The total number of diarrheal stools, weight of diarrheal stools, incidence of fever, and peak stool
V. cholerae
excretion among vaccinees were all significantly lower than in placebo recipients. Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. This vaccine may therefore be a safe and effective tool to prevent cholera in travelers and is a strong candidate for further evaluation to prevent cholera in an area where cholera is endemic.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Immunology,Microbiology,Parasitology
Reference17 articles.
1. Benenson, A. S., A. Saad, and W. H. Mosley. 1968. Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull. W. H. O.38:277-285. 2. Centers for Disease Control and Prevention. 1998. Cholera outbreak among Rwandan refugees-Democratic Republic of Congo, April 1997. Morb. Mortal. Wkly. Rep.47:389-391. 3. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, M. R. Khan, S. Huda, F. Ahmed, J. Gomes, M. R. Rao, and A. M. Svennerholm. 1989. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J. Infect. Dis.159:770-773. 4. Clements, M. L., M. M. Levine, C. R. Young, R. E. Black, Y. L. Lim, R. M. Robins-Browne, and J. P. Craig. 1982. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J. Infect. Dis.145:465-473. 5. Glass, R. I., J. Holmgren, C. E. Haley, M. R. Khan, A. M. Svennerholm, B. J. Stoll, K. M. Belayet Hossain, R. E. Black, M. Yunus, and D. Barua. 1985. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am. J. Epidemiol.121:791-796.
Cited by
90 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|